Caroline Boulton is the Global Program Head for the Malaria Flagship programs at Novartis. She is a veteran drug developer with over 20 years of experience in innovative pharmaceuticals gained at a number of different companies including Roche, Amgen and SmithKline Beecham.

Prior to joining the malaria team, Caroline led the Regulatory Affairs teams within the Early Development and Cardiovascular Units at Novartis and was responsible for ground-breaking approvals such as that of the Heart Failure drug Entresto. Over her career she has gained extensive experience working with Health Authorities around the world, helping to shape regulatory frameworks and policy.

Caroline developed her passion to contribute to the malaria eradication agenda when leading the Global Health Regulatory Affairs team supporting the Novartis malaria portfolio. She is committed to delivering transformative new malaria treatments to address the remaining unmet needs.

Caroline has a Ph.D. in Neuroscience from the University of Manchester, U.K. and a  Pharmacy degree from the University of London, U.K..